Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Pfizer and Acura Pharmaceuticals’ OXECTA Tablets CII.
Subscribe to our email newsletter
OXECTA, an immediate-release oxycodone HCl medicine, is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
OXECTA applies AVERSION Technology, which is designed to discourage common methods of tampering associated with opioid abuse and misuse.
The AVERSION Technology is a composition of commonly used pharmaceutical ingredients.
Pfizer is licensing the technology in OXECTA from Acura.
Acura will receive a $20m milestone payment from Pfizer based on the approval of OXECTA.